The Trial Demonstrated the Safety and Efficacy of the ORMD 0801- Oral
JERUSALEM, Israel, August 6 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP)(http://www.oramed.com), a developer of oral delivery systems, announced today successful results from the clinical trial of its oral insulin capsule, ORMD 0801. The trial demonstrated that the product had a good safety profile and was well tolerated and effective in lowering blood glucose levels in patients with type 2 diabetes.
The study was conducted at Hadassah University Medical Center in Jerusalem and was a continuation of the successful Phase 1B trials that Oramed completed earlier this year.
This trial was the first to expose patients with type 2 diabetes to ORMD 0801 and its primary goals were to assess the safety, tolerability and pharmcodynamic effects in these patients.
ORMD 0801 was well tolerated by all patients and had a good safety profile; no serious adverse events were encountered throughout the study. In 6 of the 9 subjects analyzed, statistically significant reductions in glucose as well as C-peptide were observed.
"We are pleased with the results from the Phase 2A trial as they showed that ORMD 0801 was effective and there were no safety issues," said Oramed's Chief Scientist, Dr. Miriam Kidron. "We look forward to our next phase of testing and taking the next steps towards making an oral insulin capsule a reality for millions of diabetics around the world."
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a technology pioneer in the field of oral
delivery solutions for drugs and vaccines presently delivered via
injection. Oramed is seeking to revolutionize the treatment of diabetes
through its patented flagship product, an orally ingestible insulin capsule
currently in phase 2 clinical trials. Established in 2006, Oramed's
|SOURCE Oramed Pharmaceuticals Inc.|
Copyright©2008 PR Newswire.
All rights reserved